FIELD: medicine.
SUBSTANCE: Interleukin 1-b 2000 U in an amount of 0.1 ml is introduced intravitreally into both rabbit's eyes. That is followed by sequential intravitreal administration of platelet-derived growth factor PDGF AA of osteoblastic sarcoma in an amount of 0.1 ml in the concentration of 2000 pcg/ml.
EFFECT: producing a clinically and cytopathogenetically adequate model of PVR applicable to study the efficacy of medicinal treatment and prevention of PVR experimentally.
2 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING PROLIFERATIVE VITREORETINOPATHY USING LIPOSOME-ASSOCIATED MELPHALAN IN AN EXPERIMENT | 2021 |
|
RU2772520C1 |
| METHOD FOR THE TREATMENT OF PROLIFERATIVE PROCESSES OF THE POSTERIOR SEGMENT OF THE EYE | 2018 |
|
RU2684927C1 |
| METHOD FOR MODELING PROLIFERATIVE VITRORETINOPATHY | 1998 |
|
RU2161335C2 |
| METHOD FOR SIMULATING PROLIFERATIVE VITREORETINOPATHY IN RATS | 2014 |
|
RU2563368C1 |
| METHOD FOR SIMULATING PROLIFERATIVE RETINOPATHY IN RATS | 2014 |
|
RU2558991C1 |
| METHOD FOR PREVENTING PROLIFERATIVE VITREORETINOPATHY | 1999 |
|
RU2175223C2 |
| METHOD OF TRANSPLANTATION OF RETINAL PIGMENT EPITHELIUM IN THE FORM OF MULTICELLULAR 3D SPHEROIDS IN EXPERIMENT | 2019 |
|
RU2704094C1 |
| METHOD FOR MODELING PROLIFERATIVE VITREORETINOPATHY | 2000 |
|
RU2182369C2 |
| TREATMENT METHOD OF AGE-RELATED MACULAR DEGENERATION | 2008 |
|
RU2368359C1 |
| METHOD FOR TREATING PROLIFERATIVE VITREORETINOPATHY | 2005 |
|
RU2284812C1 |
